Bempedoic acid (Nexletol, Esperion), an oral, once-daily, non-statin low-density lipoprotein-cholesterol lowering medicine, is now available in US pharmacies.
Ticagrelor alone, without aspirin, reduced bleeding without increasing the cardiovascular risks.
Alirocumab significantly reduced low-density lipoprotein cholesterol in adults with homozygous familial hypercholesterolemia, according to phase 3 data.
Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.
Fish oil supplementation may be associated with lower all-cause mortality, cardiovascular disease (CVD) mortality, and CVD events.
A new study found several shortcomings in blood pressure management.
The differences between antihypertension medication classes were generally small and nuanced in terms of their effect on reducing cardiovascular risks.
A secondary analysis presented at the American Stroke Association’s International Stroke Conference 2020 confirmed the safety of apixaban treatment.
Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease.
Rosiglitazone, which is used to treat type 2 diabetes, may increase the risk of heart problems.